Featuring perspectives from Dr Matthew Milowsky, Dr Peter H O’Donnell, Dr Jonathan E Rosenberg and Dr Arlene Siefker-Radtke, moderated by Dr Evan Y Yu, including the following topics:

• Introduction (0:00)
• Role of Anti-PD-1/PD-L1 Antibodies in Therapy for Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr Milowsky (2:54)
• Other Novel Strategies Under Investigation for Nonmetastatic UBC — Dr O’Donnell (25:53)
• Front-Line Treatment for Metastatic UBC (mUBC) — Dr Rosenberg (49:43)
• Emerging Role of HER2-Targeted Therapy for mUBC — Dr Yu (1:12:03)
• Selection and Sequencing of Therapy for Relapsed/Refractory mUBC — Dr Siefker-Radtke (1:35:51)

CME information and select publications